Description
AxitinibisaninhibitorofVEGFRthatexhibitsanticancerchemotherapeuticandanti-angiogenicactivities.Axitinibiscurrentlyinclinicaltrialsasapotentialtreatmentforrenalcellcarcinoma.Invitro,axitinibincreaseslevelsofCD8+Tcellsanddecreaseslevelsofmyeloid-derivedsuppressorcells,inhibitingproliferationandincreasingapoptosis.Invivo,thiscompoundinhibitsexpressionofiNOS,arginase,IL-6,TNF-α,andIFN-γ,increasingapoptosisandinhibitingtumorgrowth.Inanimalmodelsoflungadenocarcinoma,axitinibdecreasestumorvasculatureandlesiongrowth.
References
ZhangX,FangX,GaoZ,etal.Axitinib,aselectiveinhibitorofvascularendothelialgrowthfactorreceptor,exertsananticancereffectinmelanomathroughpromotingantitumorimmunity.AnticancerDrugs.2014Feb;25(2):204-11.PMID:24135499.
Gross-GoupilM,FrançoisL,QuivyA,etal.Axitinib:AReviewofitsSafetyandEfficacyintheTreatmentofAdultswithAdvancedRenalCellCarcinoma.ClinMedInsightsOncol.2013Oct29;7:269-277.PMID:24250243.
MajetiBK,LeeJH,SimmonsBH,etal.VEGFisanimportantmediatoroftumorangiogenesisinmalignantlesionsinageneticallyengineeredmousemodeloflungadenocarcinoma.BMCCancer.2013Apr29;13(1):213.[Epubaheadofprint].PMID:23627488.
